<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158299</url>
  </required_header>
  <id_info>
    <org_study_id>Clinical trail003</org_study_id>
    <nct_id>NCT02158299</nct_id>
  </id_info>
  <brief_title>Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer</brief_title>
  <official_title>Contrast The Role of Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      After Axillary lymphadenectomy for breast cancer there are not few patients showed seroma&#xD;
      formation and it can not be ignored.Investigators aimed to study two new methods of&#xD;
      application of Microfibrillar Collagen Hemostat Flour and OK-432 to reduce seroma formation&#xD;
      and to verify the efficacy and safety of these two applications.Try to prove them as&#xD;
      beneficial supplements for axillary lymphadenectomy of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective,randomized analysis of breast-conserving surgery or mastectomy plus axillary&#xD;
      lymphadenectomy for those patients with sentinel node positive using Microfibrillar Collagen&#xD;
      Hemostat Flour 、 OK-432 or using nothing in equal probability.Up to 12 months,a total of 180&#xD;
      will be recruited in plan.During the operation and after the axillary&#xD;
      lymphadenectomy，according the arms，Investigators put Microfibrillar Collagen Hemostat&#xD;
      Flour（avitene）、 OK-432（Sapylin） or nothing into patients axillary wounds。And Investigators&#xD;
      will the statistical significance of these three arms that the postoperative drainage&#xD;
      magnitude and duration.Also the complications associated with axillary lymphadenectomy will&#xD;
      be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative drainage magnitude</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the drainage</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The complications of seroma formation</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Drainage</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avitene</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapylin</intervention_name>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>axillary drainage</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>reexamine</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients volunteered for the study and signed informed consent；&#xD;
&#xD;
          2. Preoperative biopsy or intraoperative sentinel lymph node biopsy confirmed axillary&#xD;
             lymph node metastasis and need axillary lymphadenectomy&#xD;
&#xD;
          3. No penicillin allergy&#xD;
&#xD;
          4. No blood system diseases&#xD;
&#xD;
          5. No rheumatic heart disease&#xD;
&#xD;
          6. No history or family history of asthma&#xD;
&#xD;
          7. No history of axillary surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of severe hypertension&#xD;
&#xD;
          2. A history of diabetes&#xD;
&#xD;
          3. Undergoing anticoagulant therapy or anticoagulant therapy drug withdrawal less than a&#xD;
             year&#xD;
&#xD;
          4. BMI&gt;30&#xD;
&#xD;
          5. Can not accept telephone follow-up or can not go to the hospital for subsequent&#xD;
             inspection treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Wei juan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Wei juan</last_name>
    <phone>+86-20-34071157</phone>
    <email>13560328074@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Jing hua</last_name>
      <phone>+86-13560328074</phone>
      <email>jinghua87@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhao Jing hua</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jia Weijuan</investigator_full_name>
    <investigator_title>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

